Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection

Autor: Gail V. Matthews, Sanjay Bhagani, Marc Van der Valk, Juergen Rockstroh, Jordan J. Feld, Andri Rauch, Christine Thurnheer, Julie Bruneau, Arthur Kim, Margaret Hellard, David Shaw, Ed Gane, Mark Nelson, Patrick Ingiliz, Tanya L. Applegate, Jason Grebely, Phillipa Marks, Marianne Martinello, Kathy Petoumenos, Gregory J. Dore, Marc van der Valk, Greg Dore, Pip Marks, Gail Matthews, Tanya Applegate, Jordan Feld, Jürgen Rockstroh, Sophia Amjad, Elise Tu, Mahshid Tamaddoni, Maria Christine Thurnheer, Yvonne Gilleece, Chris Fraser, Alberto Moriggia, Thomas Lutz, Juhi Moon, Phillip Read, Arthur Y. Kim, Andrew Ustianowski, Christiane Cordes, Joe Sasadeusz, Mark Hull, Dominique Braun

Publikováno v: Matthews, Gail V; Bhagani, Sanjay; Van der Valk, Marc; Rockstroh, Juergen; Feld, Jordan J; Rauch, Andri; Thurnheer, Christine; Bruneau, Julie; Kim, Arthur; Hellard, Margaret; Shaw, David; Gane, Ed; Nelson, Mark; Ingiliz, Patrick; Applegate, Tanya L; Grebely, Jason; Marks, Phillipa; Martinello, Marianne; Petoumenos, Kathy; Dore, Gregory J; ... (2021). Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. Journal of hepatology, 75(4), pp. 829-839. Elsevier 10.1016/j.jhep.2021.04.056
J Hepatol
Journal of hepatology, 75(4), 829-839. Elsevier

Background & Aims Shortened duration therapy for acute and recent HCV infection has been shown to be highly effective in several small non-randomised studies with direct-acting antiviral regimens; however, large randomised studies are lacking. Method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56cb0f6e8b73a263af7310a4cfd284e8
https://boris.unibe.ch/156581/1/1-s2.0-S0168827821003366-main.pdf

Interferon Alfa

Autor: Jason Grebely, Greg Dore

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f82659bf0cef8c09ddb86bd48b987974
https://doi.org/10.1201/b13787-291

Antiretroviral therapy-related hepatotoxicity: predictors and clinical management

Autor: Greg, Dore

Publikováno v: Journal of HIV therapy. 8(4)

Severe hepatotoxicity develops in 5-10% of people with HIV infection in the first 12 months following initiation of highly-active antiretroviral therapy (HAART), with continuing risk in subsequent years. The major risk factors for severe hepatotoxici

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d6299e2b9e234dee445132f94affb8ea
https://pubmed.ncbi.nlm.nih.gov/14671507

An analysis of task difficulty using the visually degraded stimulus task

Autor: Greg Dore, Jeffery W. Elias, Keith E. Whitfield

Publikováno v: Perceptual and motor skills. 72(3 Pt 1)

This article discusses the utility of the Visually Degraded Stimulus Task developed in 1986 by Vokey, Baker, Hayman, and Jacoby. The program provides 30 line drawings that can be presented in complete form prior to receiving incomplete forms of the s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e275d069c73cdbfeeb2fec8a7a8b8eb
https://pubmed.ncbi.nlm.nih.gov/1891305